Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V C Jordan

Cancer research

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Cancer Research|August 2, 2001
Selective estrogen receptor modulation: a personal perspectiveV C Jordan
Cancer Research|October 15, 1987
Reversal of the antitumor effects of tamoxifen by progesterone in the 7,12-dimethylbenzanthracene-induced rat mammary carcinoma modelS P Robinson, V C Jordan
Cancer Research|May 15, 1996
Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell linesJ J Pink, V C Jordan
Cancer Research|September 15, 1988
Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administrationM M Gottardis, V C Jordan
Cancer Research|August 1, 1987
Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma modelM M Gottardis, V C Jordan
Cancer Research|July 15, 1990
Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lectureL J Lerner, V C Jordan
Cancer Research|August 1, 1997
MCF-7: the first hormone-responsive breast cancer cell lineA S Levenson, V C Jordan
Cancer Research|April 1, 1989
Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouseS P Robinson, V C Jordan
Cancer Research|May 15, 1998
The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptorA S Levenson, V C Jordan
Cancer Research|February 15, 1988
In vitro estrogenic actions in rat and human cells of hydroxylated derivatives of D16726 (zindoxifene), an agent with known antimammary cancer activity in vivoS P Robinson, R Koch, V C Jordan
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Cancer Research|August 2, 2001
Selective estrogen receptor modulation: a personal perspectiveV C Jordan
Cancer Research|October 15, 1987
Reversal of the antitumor effects of tamoxifen by progesterone in the 7,12-dimethylbenzanthracene-induced rat mammary carcinoma modelS P Robinson, V C Jordan
Cancer Research|May 15, 1996
Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell linesJ J Pink, V C Jordan
Cancer Research|September 15, 1988
Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administrationM M Gottardis, V C Jordan
Cancer Research|August 1, 1987
Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma modelM M Gottardis, V C Jordan
Cancer Research|July 15, 1990
Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lectureL J Lerner, V C Jordan
Cancer Research|August 1, 1997
MCF-7: the first hormone-responsive breast cancer cell lineA S Levenson, V C Jordan
Cancer Research|April 1, 1989
Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouseS P Robinson, V C Jordan
Cancer Research|May 15, 1998
The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptorA S Levenson, V C Jordan
Cancer Research|February 15, 1988
In vitro estrogenic actions in rat and human cells of hydroxylated derivatives of D16726 (zindoxifene), an agent with known antimammary cancer activity in vivoS P Robinson, R Koch, V C Jordan
Pageof 4